Sage Therapeutic Stock Buy Hold or Sell Recommendation
| SAGE Stock | USD 13.04 0.47 3.74% |
Given the investment horizon of 90 days and your complete indifference towards market risk, our recommendation regarding Sage Therapeutic is 'Strong Buy'. Macroaxis provides Sage Therapeutic buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding SAGE positions. The advice algorithm takes into account all of Sage Therapeutic's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Sage Therapeutic's buy or sell advice are summarized below:
Real Value 15.64 | Target Price 25.71 | Hype Value 10.96 | Market Value 13.04 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Sage Therapeutic given historical horizon and risk tolerance towards Sage Therapeutic. When Macroaxis issues a 'buy' or 'sell' recommendation for Sage Therapeutic, the advice is generated through an automated system that utilizes algorithms and statistical models.
Sage |
Execute Sage Therapeutic Buy or Sell Advice
The Sage recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Sage Therapeutic. Macroaxis does not own or have any residual interests in Sage Therapeutic or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Sage Therapeutic's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Buy
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Sage Therapeutic Trading Alerts and Improvement Suggestions
| Sage Therapeutic generated a negative expected return over the last 90 days | |
| Sage Therapeutic has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 86.45 M. Net Loss for the year was (541.49 M) with loss before overhead, payroll, taxes, and interest of (319.29 M). | |
| Sage Therapeutic currently holds about 1.51 B in cash with (540.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 25.47, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Acquisition by Anne Cook of 2850 shares of Sage Therapeutic subject to Rule 16b-3 |
Sage Therapeutic current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Sage analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Sage analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Sage Therapeutic Returns Distribution Density
The distribution of Sage Therapeutic's historical returns is an attempt to chart the uncertainty of Sage Therapeutic's future price movements. The chart of the probability distribution of Sage Therapeutic daily returns describes the distribution of returns around its average expected value. We use Sage Therapeutic price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Sage Therapeutic returns is essential to provide solid investment advice for Sage Therapeutic.
| Mean Return | -1.06 | Value At Risk | -4.75 | Potential Upside | 2.26 | Standard Deviation | 3.67 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Sage Therapeutic historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Sage Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sage Therapeutic is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sage Therapeutic backward and forwards among themselves. Sage Therapeutic's institutional investor refers to the entity that pools money to purchase Sage Therapeutic's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Palo Alto Investors, Llc | 2023-12-31 | 991.5 K | Dimensional Fund Advisors, Inc. | 2023-12-31 | 967.7 K | Goldman Sachs Group Inc | 2023-12-31 | 953 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 870.6 K | Samlyn Capital, Llc | 2023-12-31 | 768.9 K | Northern Trust Corp | 2023-12-31 | 542.7 K | Alyeska Investment Group, L.p. | 2023-09-30 | 528.8 K | T. Rowe Price Associates, Inc. | 2023-12-31 | 478.1 K | Fisher Asset Management, Llc | 2023-12-31 | 431.9 K | Wellington Management Company Llp | 2023-12-31 | 6.1 M | Fmr Inc | 2023-12-31 | 5.5 M |
Sage Therapeutic Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (64.2M) | 1.5B | (1.4B) | (131.5M) | (91.6M) | (87.1M) | |
| Free Cash Flow | (534.5M) | 663.9M | (378.6M) | (461.0M) | (541.1M) | (514.1M) | |
| Depreciation | 2.3M | 2.6M | 4.2M | 1.1M | 1.4M | 1.3M | |
| Capital Expenditures | 5.8M | 345K | 372K | 937K | 553K | 525.4K | |
| Net Income | (680.2M) | 606.1M | (457.9M) | (532.8M) | (541.5M) | (514.4M) | |
| End Period Cash Flow | 129.1M | 1.7B | 295.5M | 164.0M | 72.3M | 68.7M | |
| Other Non Cash Items | (10.6M) | (688K) | (10.6M) | 4.4M | (6.5M) | (6.1M) | |
| Investments | (137.4M) | 443.0M | (1.0B) | 326.4M | 490.6M | 515.2M | |
| Change To Netincome | 149.6M | 94.3M | 94.0M | 60.1M | 69.1M | 70.3M |
Sage Therapeutic Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Sage Therapeutic or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Sage Therapeutic's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Sage stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -1.15 | |
β | Beta against NYSE Composite | 1.94 | |
σ | Overall volatility | 3.73 | |
Ir | Information ratio | -0.3 |
Sage Therapeutic Volatility Alert
Sage Therapeutic exhibits very low volatility with skewness of -1.51 and kurtosis of 10.93. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Sage Therapeutic's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Sage Therapeutic's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Sage Therapeutic Fundamentals Vs Peers
Comparing Sage Therapeutic's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Sage Therapeutic's direct or indirect competition across all of the common fundamentals between Sage Therapeutic and the related equities. This way, we can detect undervalued stocks with similar characteristics as Sage Therapeutic or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Sage Therapeutic's fundamental indicators could also be used in its relative valuation, which is a method of valuing Sage Therapeutic by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Sage Therapeutic to competition |
| Fundamentals | Sage Therapeutic | Peer Average |
| Return On Equity | -0.53 | -0.31 |
| Return On Asset | -0.31 | -0.14 |
| Operating Margin | (0.54) % | (5.51) % |
| Current Valuation | 191.45 M | 16.62 B |
| Shares Outstanding | 60.11 M | 571.82 M |
| Shares Owned By Insiders | 12.56 % | 10.09 % |
| Shares Owned By Institutions | 95.54 % | 39.21 % |
| Number Of Shares Shorted | 8.6 M | 4.71 M |
| Price To Earning | 3.07 X | 28.72 X |
| Price To Book | 1.16 X | 9.51 X |
| Price To Sales | 10.73 X | 11.42 X |
| Revenue | 86.45 M | 9.43 B |
| Gross Profit | (319.29 M) | 27.38 B |
| EBITDA | (511.68 M) | 3.9 B |
| Net Income | (541.49 M) | 570.98 M |
| Cash And Equivalents | 1.51 B | 2.7 B |
| Cash Per Share | 25.47 X | 5.01 X |
| Total Debt | 5.17 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 17.69 X | 2.16 X |
| Book Value Per Share | 13.32 X | 1.93 K |
| Cash Flow From Operations | (540.59 M) | 971.22 M |
| Short Ratio | 10.28 X | 4.00 X |
| Earnings Per Share | (9.05) X | 3.12 X |
| Price To Earnings To Growth | 0.74 X | 4.89 X |
| Target Price | 28.0 | |
| Number Of Employees | 487 | 18.84 K |
| Beta | 0.85 | -0.15 |
| Market Capitalization | 939.47 M | 19.03 B |
| Total Asset | 882.28 M | 29.47 B |
| Retained Earnings | (2.57 B) | 9.33 B |
| Working Capital | 786.6 M | 1.48 B |
| Current Asset | 188.49 M | 9.34 B |
Note: Acquisition by Kimi Iguchi of 3000 shares of Sage Therapeutic at 1.36 subject to Rule 16b-3 [view details]
Sage Therapeutic Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Sage . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Sage Therapeutic Buy or Sell Advice
When is the right time to buy or sell Sage Therapeutic? Buying financial instruments such as Sage Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 67.3M | 72.7M | 67.3M | 44.1M | Total Assets | 1.8B | 1.4B | 882.3M | 873.1M |
Use Investing Ideas to Build Portfolios
In addition to having Sage Therapeutic in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Recreation Thematic Idea Now
Recreation
Companies involved in production and services of recreational goods, foods, and accessories. The Recreation theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Recreation Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Sage Therapeutic Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.Note that the Sage Therapeutic information on this page should be used as a complementary analysis to other Sage Therapeutic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for Sage Stock analysis
When running Sage Therapeutic's price analysis, check to measure Sage Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sage Therapeutic is operating at the current time. Most of Sage Therapeutic's value examination focuses on studying past and present price action to predict the probability of Sage Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sage Therapeutic's price. Additionally, you may evaluate how the addition of Sage Therapeutic to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Sage Therapeutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.05) | Revenue Per Share 1.445 | Quarterly Revenue Growth 26.215 | Return On Assets (0.31) | Return On Equity (0.53) |
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.